Persistent enterocyte damage despite decreased microbial translocation in patients on effective antiretroviral therapy

Intestinal fatty acid binding protein (I‐FABP) was proposed as a plasma marker of enterocyte turnover that could be applied to estimate the level of gut damage in HIV‐1 infected patients. We investigated the kinetics of I‐FABP in patients starting antiretroviral therapy (ART) in a clinical cohort (C...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International AIDS Society 2012-11, Vol.15 (S4), p.1-1
Main Authors: Nowak, P, Vesterbacka, J, Barqasho, B, Funaoka, H, Kanda, T, Gisslen, M, Sönnerborg, A
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Antiretroviral agents
Antiretroviral drugs
Drug therapy
Translocation
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intestinal fatty acid binding protein (I‐FABP) was proposed as a plasma marker of enterocyte turnover that could be applied to estimate the level of gut damage in HIV‐1 infected patients. We investigated the kinetics of I‐FABP in patients starting antiretroviral therapy (ART) in a clinical cohort (CC) (n=32), and in a clinical trial (RCT), where patients were randomized to lopinavir/r (LPV/r) or efavirenz (EFV)‐based therapy (n=71). I‐FABP was analyzed at baseline (BL) and after 48 and 72 weeks of ART, respectively. Additionally we estimated levels of LPS and sCD14 in both cohorts. At baseline, we found elevated plasma levels of I‐FABP, LPS, and sCD14 in patients with HIV‐1 infection as compared to controls. During ART I‐FABP levels increased from BL to week 48 (1.66 ng/ml [IQR 1.29–2.88] vs. 2.56 ng/ml [IQR 1.29–5.26]; p=0.02) in CC group. Similar pattern was seen in the RCT group at week 72 as compared to BL (2.26 ng/ml [IQR 1.4–3.6] vs 3.13 ng/ml [IQR 1.8–4.9]; p
ISSN:1758-2652
1758-2652
DOI:10.7448/IAS.15.6.18142